The PHYOX clinical trial of DCR-PHXC is a Phase I, single-ascending dose study of DCR-PHXC in patients with primary hyperoxaluria (PH) type 1 (PH1) and type 2 (PH2). A single-ascending dose study is when a single dose of a treatment is given to a small group of participants. If the dose is well-tolerated, researchers may raise the dose in order to determine the highest safe dose.
- Evaluate the safety and tolerability of single doses of DCR-PHXC
- Evaluate the pharmacodynamic (PD) effects of single doses of DCR-PHXC on biochemical markers including, but not limited to, changes in urine oxalate concentrations
- Characterize the pharmacokinetics (PK) of single doses of DCR-PHXC in patients with PH
Pharmacodynamics is the study of how a drug affects the body, whereas pharmacokinetics is the study of how drugs move within the body.
Participating in the Trial
Physicians at leading research institutions who specialize in the treatment of PH are conducting the PHYOX clinical trials. If you or a loved one has been diagnosed with PH and would like to participate in the clinical trial, please view the Clinical Trial Sites page for the trial center nearest to you. To find out if you qualify for the trial you may:
- Contact the clinical site via the contact form through this website
- Call the clinical site directly
Key Participation Criteria
You may be eligible to participate in the trial if you:
- Male or female, 6 years of age or older
- Minimum body weight of 25 kg
- Diagnosed with PH1 or PH2
- Meet the 24-hour urine oxalate excretion requirements
- Consent from patient or guardian (if the patient is a minor)